Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | VNN1 | O95497 | 5/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 5/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066477 | 0.86 | CES2 (0.46) | CES2CES1VNN1NTSR1KCNQ3 | |
| SCHEMBL2883258 | 0.80 | CES2 (0.48) | CES2CES1VNN1KCNQ3KCNQ2 | |
| SCHEMBL2882494 | 0.78 | CES2 (0.43) | CES2CES1VNN1KCNQ3KCNQ2 | |
| SCHEMBL27762073 | 0.76 | PARP1 (0.38) | — | |
| SCHEMBL7967901 | 0.72 | CES2 (0.73) | CES2CES1VNN1KCNQ3KCNQ2 | |
| SCHEMBL21394746 | 0.68 | PPARG (0.39) | KCNQ3KCNQ2 | |
| SCHEMBL12975496 | 0.68 | VNN1 (0.56) | CES2CES1VNN1KCNQ3KCNQ2 | |
| SCHEMBL12975456 | 0.68 | VNN1 (0.51) | CES2CES1VNN1KCNQ3KCNQ2 | |
| SCHEMBL12975504 | 0.68 | VNN1 (0.54) | CES2CES1VNN1KCNQ3KCNQ2 | |
| SCHEMBL2126134 | 0.68 | CES2 (0.59) | CES2CES1NTSR1PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | CES2 1262/4885CES1 758/4885VNN1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.